Cargando…
Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
BACKGROUND: Entecavir (ETV) is recommended as a first-line anti-HBV treatment. However, many chronic hepatitis B patients initiate anti-HBV treatment such as lamivudine and telbivudine with low genetic barriers in China, which leads to compensatory mutations and increases the rate of ETV resistance....
Autores principales: | Shang, Jin, Zhou, Juan, Liu, Huan, Ise, Rili M., Tu, You, Ran, Jinqiu, Bai, Lang, Tang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420064/ https://www.ncbi.nlm.nih.gov/pubmed/34488678 http://dx.doi.org/10.1186/s12879-021-06554-1 |
Ejemplares similares
-
Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy
por: Liang, Ling-Bo, et al.
Publicado: (2015) -
High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
por: Chae, Hee Bok, et al.
Publicado: (2012) -
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017) -
Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015) -
Safety and efficacy of entecavir for the treatment of chronic hepatitis B
por: Osborn, Melissa
Publicado: (2011)